# A Phase 1b/2 Trial of the Safety and Microbiological Activity of Bacteriophage Therapy in Cystic Fibrosis Subjects Colonized With Pseudomonas Aeruginosa

> **NCT05453578** · PHASE1,PHASE2 · COMPLETED · sponsor: **National Institute of Allergy and Infectious Diseases (NIAID)** · enrollment: 72 (actual)

## Conditions studied

- Bacterial Disease Carrier
- Cystic Fibrosis

## Interventions

- **OTHER:** Placebo
- **BIOLOGICAL:** WRAIR-PAM-CF1

## Key facts

- **NCT ID:** NCT05453578
- **Lead sponsor:** National Institute of Allergy and Infectious Diseases (NIAID)
- **Sponsor class:** NIH
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-10-03
- **Primary completion:** 2025-04-10
- **Final completion:** 2025-04-10
- **Target enrollment:** 72 (ACTUAL)
- **Last updated:** 2025-12-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05453578

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05453578, "A Phase 1b/2 Trial of the Safety and Microbiological Activity of Bacteriophage Therapy in Cystic Fibrosis Subjects Colonized With Pseudomonas Aeruginosa". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT05453578. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*